phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies

Blagden S., Spiliopoulou P., Spiers L., Gnanaranjan C., Qi C., Woodcock VK., Moschandreas J., Tyrrell HEJ., Griffiths L., Butcher C., Ghazaly E., Evans TRJ.

DOI

10.1093/annonc/mdy279.429

Type

Conference paper

Publication Date

2018-10-01T00:00:00+00:00

Volume

29

Permalink More information Close